EE04391B1 - Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid - Google Patents

Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid

Info

Publication number
EE04391B1
EE04391B1 EEP200000589A EEP200000589A EE04391B1 EE 04391 B1 EE04391 B1 EE 04391B1 EE P200000589 A EEP200000589 A EE P200000589A EE P200000589 A EEP200000589 A EE P200000589A EE 04391 B1 EE04391 B1 EE 04391B1
Authority
EE
Estonia
Prior art keywords
superlaggregates
tablets
formulations
making
methods
Prior art date
Application number
EEP200000589A
Other languages
English (en)
Estonian (et)
Inventor
T. Makooi-Morehead William
D. Buehler John
R. Landmann Brian
Original Assignee
Dupont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04391(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dupont Pharmaceuticals Company filed Critical Dupont Pharmaceuticals Company
Publication of EE200000589A publication Critical patent/EE200000589A/xx
Publication of EE04391B1 publication Critical patent/EE04391B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000589A 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid EE04391B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07
PCT/US1999/007228 WO1999051239A1 (en) 1998-04-07 1999-04-01 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Publications (2)

Publication Number Publication Date
EE200000589A EE200000589A (et) 2002-04-15
EE04391B1 true EE04391B1 (et) 2004-12-15

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000589A EE04391B1 (et) 1998-04-07 1999-04-01 Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid

Country Status (27)

Country Link
US (2) US6238695B1 (uk)
EP (1) EP1067936B1 (uk)
JP (1) JP2002510634A (uk)
KR (1) KR100634253B1 (uk)
CN (1) CN1146419C (uk)
AR (1) AR019031A1 (uk)
AT (1) ATE223719T1 (uk)
AU (1) AU756422B2 (uk)
BR (1) BR9908810A (uk)
CA (1) CA2321523C (uk)
CZ (1) CZ300850B6 (uk)
DE (1) DE69902893T2 (uk)
DK (1) DK1067936T3 (uk)
EA (1) EA003217B1 (uk)
EE (1) EE04391B1 (uk)
ES (1) ES2181417T3 (uk)
HU (1) HU228498B1 (uk)
IL (1) IL138078A (uk)
NO (1) NO325824B1 (uk)
NZ (1) NZ507566A (uk)
PL (1) PL194309B1 (uk)
PT (1) PT1067936E (uk)
SK (1) SK284655B6 (uk)
TW (1) TW576741B (uk)
UA (1) UA72207C2 (uk)
WO (1) WO1999051239A1 (uk)
ZA (1) ZA200004313B (uk)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
US6177101B1 (en) * 1998-06-11 2001-01-23 Pharmacia & Upjohn Company Delavirdine high strength tablet formulation
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
US20030124186A1 (en) * 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
AU2004206821C1 (en) 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8021682B2 (en) * 2004-08-13 2011-09-20 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
JP5243247B2 (ja) * 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
US20080317852A1 (en) * 2005-12-14 2008-12-25 Amar Lulla Pharmaceutical Combination
WO2008008120A1 (en) * 2006-07-14 2008-01-17 Fmc Corporation Solid form
WO2008033487A2 (en) * 2006-09-14 2008-03-20 Chemlink Laboratories Llc Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
EP2125938A2 (en) * 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2009026257A2 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
TR201807704T4 (tr) 2010-01-27 2018-06-21 Viiv Healthcare Co Anti-viral tedavi.
KR20130076818A (ko) * 2010-04-20 2013-07-08 시플라 리미티드 약학 조성물
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
IN2013MU03370A (uk) 2013-10-25 2015-09-25 Cipla Ltd
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017029226A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005804A1 (en) 1986-04-01 1987-10-08 The Upjohn Company Methylprednisolone/sodium carboxymethyl starch tablet composition
HU205717B (en) * 1989-04-28 1992-06-29 Daiichi Seiyaku Co Process for producing pharmaceutical composition against human immunodeficiency, comprising pyridionecarboxylic acid derivative
ATE154513T1 (de) * 1992-07-08 1997-07-15 Leiras Oy Augenarzneimittel enthaltend timolol hemihydrat
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz

Also Published As

Publication number Publication date
PL194309B1 (pl) 2007-05-31
AR019031A1 (es) 2001-12-26
NZ507566A (en) 2002-11-26
DE69902893D1 (de) 2002-10-17
EA200001030A1 (ru) 2001-04-23
PT1067936E (pt) 2002-12-31
NO20005043L (no) 2000-10-06
WO1999051239A1 (en) 1999-10-14
ZA200004313B (en) 2002-01-30
EE200000589A (et) 2002-04-15
CA2321523A1 (en) 1999-10-14
SK284655B6 (sk) 2005-08-04
CZ20003571A3 (cs) 2001-01-17
IL138078A (en) 2005-12-18
JP2002510634A (ja) 2002-04-09
SK14612000A3 (sk) 2001-07-10
CA2321523C (en) 2008-10-07
HUP0101517A2 (hu) 2001-11-28
CN1296412A (zh) 2001-05-23
IL138078A0 (en) 2001-10-31
BR9908810A (pt) 2000-12-19
US6238695B1 (en) 2001-05-29
US20010012518A1 (en) 2001-08-09
HUP0101517A3 (en) 2002-11-28
DK1067936T3 (da) 2003-02-17
US6555133B2 (en) 2003-04-29
TW576741B (en) 2004-02-21
AU3463799A (en) 1999-10-25
EP1067936A1 (en) 2001-01-17
UA72207C2 (uk) 2005-02-15
CN1146419C (zh) 2004-04-21
AU756422B2 (en) 2003-01-09
DE69902893T2 (de) 2003-04-30
ES2181417T3 (es) 2003-02-16
PL343421A1 (en) 2001-08-13
HU228498B1 (en) 2013-03-28
NO325824B1 (no) 2008-07-21
EA003217B1 (ru) 2003-02-27
KR100634253B1 (ko) 2006-10-16
NO20005043D0 (no) 2000-10-06
EP1067936B1 (en) 2002-09-11
KR20010042473A (ko) 2001-05-25
ATE223719T1 (de) 2002-09-15
CZ300850B6 (cs) 2009-08-26

Similar Documents

Publication Publication Date Title
EE04391B1 (et) Kiirlahustuvate efavirenskapslite või -tablettideformulatsioonid, kasutades superlagundeid, ning nende valmistamise meetodid
NO996433D0 (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
IS5747A (is) Oxazólidínón afleiður, aðferð fyrir framleiðslu þeirra og lyfjasamsetninga sem innihalda þær
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
NO971485D0 (no) Antineoplastiske kakaoekstrakter, metoder for fremstilling og anvendelse
NO20004643D0 (no) Polymerbaserte raskt oppløselige tabletter og fremgangsmÕte for fremstilling derav
DK1112266T3 (da) Substituerede 4-amino-2-arylpyrimidiner, fremstilling og anvendelse deraf og farmaceutiske præparater indeholdende dem
PL338143A1 (en) Derivatives acylpiperazinylpyrimidines, method of obtaining and drugs containing them
IS5662A (is) Þíenýlasólýlalkoxýetanamín, framleiðsla þeirra ognotkun sem lyf
NO20032332L (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
IS2821B (is) Amínóalkýlbensóýl-bensófúran eða bensóþíófenafleiður, aðferð til framleiðslu þeirra og samsetningar sem innihalda þær
NO20012963D0 (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
NO20015659L (no) Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
EE200100711A (et) Naftüridiini derivaadid, nende valmistamismeetod ning neid sisaldav farmatseutiline kompositsioon
PL350902A1 (en) Pyridothiene diazepins, method of obtaining them and pharmacological compositions containing them
PL342453A1 (en) Biphenylsulphonylcyanamides, method of obtaining them and their application as drugs
EE04553B1 (et) 15-llilised 8a- ja 9a-laktaamid ning nende valmistamismeetod
HK1047407A1 (en) Polymorphs of n-methyl-n-(3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜ-pyrimidin-7-ylÜphenyl)acetamide and compositions and methods related thereto.
ZA99168B (en) Pharmaceutical formulations and processes for their preparation.
HUP0102116A3 (en) Paroxetine ascorbate, process for its preparation and its pharmaceutical use
SI1067936T1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
PL332894A1 (en) Hadgehog protein conjugate, method of obtaining same, pharmaceutic composition and method of obtaining same, hedgehog protein
TR199900070A3 (tr) Naftiridonlarin ve ara baglarin hazirlanmasina yönelik islem.
EE200100474A (et) Antratsükliinide L-arabinodisahhariidid, nende valmistamise meetodid ning neid sisaldavad ravimkoostised
DK1047668T3 (da) Triazepinoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231